Drug Search Results
More Filters [+]

Modakafusp alfa

Alternative Names: modakafusp alfa, tak-573, tak573, tak 573
Latest Update: 2024-07-19
Latest Update Note: Clinical Trial Update

Product Description

Modakafusp alfa (previously known as TAK-573) is a first-in-class immunocytokine designed to deliver interferon alpha-2b (IFNalpha2b) to CD38+ cells. It consists of two attenuated IFNalpha2b molecules genetically fused to the Fc portion of a humanized, anti-CD38, IgG4 monoclonal antibody (mAb). The specificity for CD38 and reduced IFN receptor binding affinity of the attenuated IFNalpha2b molecules significantly reduces the potential for off-target binding and toxicity. Furthermore, modakafusp alfa binds to a different epitope on CD38 than the currently approved anti-CD38 therapeutic mAbs, daratumumab and isatuximab. Preclinical evaluation of modakafusp alfa supports activation of type I IFN signaling in CD38+ cells, inducing direct anti-proliferative effects on myeloma cells, as well as direct and indirect immune cell activation. (Sourced from: https://www.myeloma.org/videos/modakafusp-alfa-tak-573-immunocytokine-patients-relapsedrefractory-multiple-myeloma-updated)

Mechanisms of Action: CD38 Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Modakafusp alfa

Countries in Clinic: Australia, Belgium, Canada, China, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Norway, Puerto Rico, South Korea, Spain, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 9

Highest Development Phases

Phase 2: Melanoma|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A Safety and Preliminary Efficacy, Pharmacokinetics, and Immunogenicity Study

P2

Active, not recruiting

Multiple Myeloma

2030-04-11

2022-001418-20

P2

Active, not recruiting

Multiple Myeloma

2028-02-13

2022-002169-14

P2

Active, not recruiting

Multiple Myeloma

2025-04-23

iinnovate-3

P2

Active, not recruiting

Multiple Myeloma

2025-03-04

47%

Recent News Events